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1. Introduction 
Type 1 diabetes (T1D) is considered as a complex genetic trait: not only do multiple genetic 
loci contribute to susceptibility, but environmental factors also play a major role in 
determining risk. A large body of evidence indicates that inherited genetic factors influence 
both susceptibility and resistance to the disease. There is significant familial clustering of 
T1D with an average prevalence risk in siblings of 7% and in a child of diabetic of 6%, 
compared to 0.4% in the general population. The degree of clustering of disease in families 
can be estimated from the ration of the risk for siblings or a patient with the disease and the 
population prevalence of that disease. If this ratio (λs) is close to 1, there is no evidence for 
familial clustering. For T1D, the degree of familial clustering λs is about 15 (6/0.4%), which 
means that if a family has a child with T1D, then the other siblings are at a 15 times greater 
risk of developing diabetes than a member of the general population.    
Genetic susceptibility in family members is clearly dependent on the degree of genetic identity 
with the proband, and in fact the risk of T1D in families has a non-linear correlation with the 
number of alleles shared with the proband; the highest risk is observed in monozygotic twins 
(100% sharing), followed by first and second degree relatives (50% and 25 % sharing 
respectively). Study of monozygotic twins provides a good opportunity to examine the 
expression of a human trait in a fixed genetic background: the absolute risk of a monozygotic 
twin of an effected individual gives a direct estimate of penetrance of this trait for a given 
environment. Although increased concordance rate for T1D has been found in monozygotic 
twins compared to dizygotic ones, it only reaches 40-50% with long-term follow-up. 
The genetics of T1D has a long history of studies evaluating candidate genes for association 
with disease status in either case-control or family-based studies. Four chromosomal regions 
have emerged with consistent and significant evidence of association with T1D across 
multiple studies. These are the major locus - the human leukocyte antigen (HLA) region - on 
chromosome 6p21, the protein tyrosine phosphatase non receptor 22 (PTPN22) gene on 
chromosome 1p13, the insulin (INS) gene region on chromosome 11p15 and the high-affinity 
alpha chain of IL-2 receptor (IL2RA) gene on chromosome 10p15.  
2. Strategies for identifying disease predisposing genes 
Until very recently, three basic approaches have been used to identify genetic variants that 
may contribute to any human phenotype, including autoimmune disorders (Gregersen & 
Olsson, 2009). These approaches are a) candidate gene association studies, b) linkage 
analysis in multiplex families, and c) genome-wide association studies/scans (GWAS). 
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Candidate gene studies have been a mainstay for human genetic studies for several decades, 
and they will continue to play an important role. However, early candidate gene case-
control studies often suffered from insufficient statistical power owing to inadequate sample 
sizes and to a lack of appreciation for the importance of careful matching of cases and 
controls. The strong publication bias for initial positive findings has been clearly 
documented (Ioannidis et al., 2001), and reports of candidate gene associations should be 
viewed with caution until multiple replications have been carried out. Candidate gene 
studies are usually done to address a plausible hypothesis, but plausibility should not 
mitigate the requirement for robust and reproducible statistical evidence. 
Genetic linkage analysis depends on the cosegregation of chromosomal regions with a 
phenotypic trait within families, as is typical for highly penetrant Mendelian disorders. For 
most common autoimmune diseases, familial aggregation is rather modest, and therefore 
linkage analysis has quite low statistical power to detect chromosomal regions with shared 
genetic risk within families. Nevertheless, linkage approaches have occasionally contributed 
significantly to the identification of new risk genes. 
In the last four years, GWAS have dominated efforts in gene mapping for autoimmune 
diseases, and these studies have led to the majority of the new genetic associations discussed 
in this review. Like candidate gene studies, the analysis is based on association, but in the 
case of GWAS, no particular hypothesis is being addressed. Rather, hundreds of thousands 
of hypotheses are being addressed simultaneously, without regard to biologic plausibility. 
This is a purely discovery-driven approach to gene identification, free of the limitations 
imposed by a priori assumptions about which genes and pathways are likely to be involved 
in the disease under study. Despite early skepticism, GWAS has proved to be a remarkably 
effective method of gene discovery. 
Although the initial sequence of the human genome was an important first step, it is really 
the International HapMap Project that has provided the basis for a rational approach to 
GWAS (Frazer et al., 2007). When considering single nucleotide polymorphisms (SNPs), any 
two unrelated individuals in the population differ by approximately 0.1% across the 3.2 
billion base pairs of the genome, or approximately 3 million SNPs. By studying 90 
individuals in families from three major racial groups (Caucasian, Asian, and African), the 
HapMap Project has cataloged the majority of the common SNPs (e.g., SNPs with minor 
allele frequencies of 5% or greater) in these populations. 
An important result of the HapMap Project has been the realization that to define most of 
the common variations among individuals, it is not necessary to genotype all 3 million SNP 
differences among them, but only a subset of these, on the order of 300,000 to 500,000 SNPs. 
This is because SNP alleles are distributed non-randomly among individuals, forming 
blocks of linkage disequilibrium (LD) that may extend from thousands to many hundreds of 
thousands of base pairs. This results in a kind of bar code that can be used to define the 
common genetic variation across the genome of a given individual.  
This pattern of common variation across genomes had led to the concept of tagging SNPs 
(Chapman et al., 2003). This involves the use of a single SNP to tag a block of LD formed by 
many other SNPs, thus allowing for the interrogation of a large section of the genome with a 
single marker. A large block of LD encompasses several genes. Thus, many SNPs in this 
region are likely to provide evidence of association for diseases that are associated with the 
certain marker. Conversely, any association observed with such a SNP may be due to causal 
variants in any of the genes in this LD block. Additional functional and biological evidence, 
that this gene is involved in autoimmunity, is necessary to prove that the gene is the 
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relevant risk gene in this region or that the marker used to first detect the association is 
causative. Once a SNP association is observed and confirmed, much work remains to be 
done to establish which genetic variants in the region are actually responsible (e.g., 
causative) for the association. 
Furthermore, because many GWAS employ 500,000 or more SNPs across the genome, each 
addressing a separate hypothesis, the statistical significance levels must be adjusted for 
multiple testing. An overall p value of  5 x 10-7 is now widely accepted as compelling 
evidence of true association, although it is quite clear that lower degrees of statistical 
significance often reflect real associations. In any case, truly convincing association always 
requires multiple replications in independent data sets. 
A major consideration for GWAS, as well as any case-control association study, is the issue 
of proper matching of cases and controls. The availability of genome-wide SNP data across 
many different populations has now permitted the use of so-called ancestry informative 
markers (AIMS) to match more precisely cases and controls for their ethnic background. 
This is quite straightforward for major racial groups, such as Asian, Caucasian, and African, 
but is more challenging within these groups (Seldin & Price, 2008). Polymorphisms in 
European Caucasian populations nicely illustrate this problem. The certain SNP displays a 
wide range of allele frequencies in the normal population, generally increasing in frequency 
going from southern to northern Europe. Therefore, if the cases and controls are taken from 
different European subpopulations, there is considerable risk of false positive (or negative) 
results. This phenomenon is generally referred to as population stratification. In the 
experience of many investigators, self-report by study participants is an unreliable indicator 
of ancestry, but in the context of GWAS, it is possible to correct for unknown population 
stratification using the entire set of SNP markers. 
Most of the associations with autoimmunity involve the detection of odds ratios between 1 
and 2, with many associations on the lower end of this range. The sample sizes required to 
generate statistical significance in the setting of GWAS (p  5 x 10-7) can be very large, 
depending on the allele frequency in the population and the odds ratios to be detected. For 
risk ratios on the order of 2 or more, sample sizes of 1000 are generally adequate. However, 
for risk ratios in the range of 1.2-1.3, even sample sizes of three or four thousand may have 
low statistical power depending on marker allele frequency (Iles, 2008). This magnitude of a 
population sample is now considered a minimum for a thorough analysis in the setting of a 
GWAS, and truly comprehensive genetic studies will require considerably larger sample 
sizes to be studied in the future. 
3. HLA genes 
The best evidence for a genetic component in the susceptibility to T1D comes from studies of 
the HLA genes in both populations and families as well as from animal models. It has been 
estimated that HLA provides up to 40-50% of the familial clustering of T1D. The 
contribution of the HLA region is easily detectable in genome-wide linkage analyses, as 
indicated by a LOD score of 65.8.   
The HLA (human leukocyte antigens) region is a cluster of genes located within the major 
histocompatibility complex (MHC) on chromosome 6p21.3 (Mungall et al., 2003). MHC is a 
region of 4 million base pairs, what is 0.1% of the human genome. It contains over 100 genes, 
which are characterized by high degree of allele polymorphism. The human MHC is 
divided into three regions: class I, class II, and class III. HLA class I genes are located 
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telomeric in the complex. They have single polypeptide chain containing 3 domains 
associated with ǃ2-microglobuline. The class I genes classically are HLA-A, -B and -C 
molecules. They are expressed on the surface of almost all tissue cells and their function is to 
present peptide antigens to CD8+ cytotoxic T-cells. HLA class II genes are located at the 
centromeric end of MHC and occupy a region of 1 million base pairs. Class II molecules are 
heterodimeric proteins consisting of heavy ǂ-chain and lighter ǃ-chain. Molecules are 
expressed on antigen presenting cells (monocytes, macrophages, B lymphocytes, dendritic 
cells and activated T lymphocytes). The HLA class II genes are HLA-DR, -DQ and –DP 
molecules and their major function is to present peptide antigens to CD4+ T-cells. The MHC 
class III region contains many genes with varying functions. The most studied genes are 
tumour necrosis factor and lymphotoxin (TNFA and TNFB). 
The state of the immune tolerance to self antigens is maintained by a complex network of T 
and B lymphocytes and their regulatory products. The mechanisms, by which this 
discrimination between ‘self’ and ‘non-self’ is established, involved central thymic tolerance 
and peripheral or post-thymic tolerance (Roitt, Brostoff, Male, 2002). Central thymic 
tolerance to self antigens (autoantigens) results from deletion of differentiating T-cells that 
express antigen-specific receptors with high binding affinity for the HLA-peptide complex, 
where peptide antigen belongs to intrathymic self peptide antigens (negative selection). 
Low-affinity self-reactive T-cells, and T-cells with receptors specific for the HLA-peptide 
complex, where peptide antigens are not represented intrathymically, mature and join the 
peripheral T-cell pool (positive selection). Post-thymic tolerance to self antigens has five 
main mechanisms. Self-reactive T-cells in the circulation may ignore self antigens, for 
example when the antigens are in tissues sequestered from the circulation. Their response to 
a self antigen may be suppressed if the antigen is present in a privileged site. Self-reactive 
cells may under certain conditions be deleted or rendered anergic and unable to respond. 
Finally a state of tolerance to self antigens can also be maintained by immune regulation. 
B-cell deletion takes place in both bone marrow and peripheral lymphoid organs. 
Differentiating B-cells that express surface immunoglobulin receptors with high binding 
affinity for self-membrane-bound antigens will be deleted soon after their generation in the 
bone marrow. A high proportion of short-lived, low-avidity, autoreactive B-cells appear in 
peripheral lymphoid organs. These cells may be recruited to fight against infection. From 
this point of view towards the HLA molecules, the discovery of function of HLA-DO, that is 
mainly expressed in B-cells and involved in antigenic peptide binding to HLA class II 
molecules in the endocytic pathway, has triggered interesting hypothesis. 
The pathway resulting in the antigen processing and presentation of peptides on HLA class 
II begins with the biosynthesis of the HLA class II ǂ and ß chains in the endoplasmic 
reticulum, where they form a trimeric complex with a co-expressed protein called invariant 
chain. The invariant chain, which fills the peptide-binding groove of the HLA class II 
molecule, directs the HLA class II molecule first to the Golgi and secondly to a specialized 
MHC class II compartment in the endosomal/lysosomal pathway. Here, invariant chain is 
proteolytically degraded in a stepwise fashion until only a fragment remains bound to the 
HLA class II molecule, called the class II-associated invariant chain peptide (CLIP). The 
exchange of CLIP for the stably binding antigenic peptides in the compartment is catalyzed 
by a specialized lysosomal chaperone called HLA-DM. The HLA class II peptide complexes 
are then transported to the cell surface for recognition by the CD4+ T lymphocytes.  
HLA-DO molecule, expressed in B-cells, associates with DM thereby markedly affecting DM 
function. DO forms a unique, cell type-specific modulator that masters the immune 
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response induced by B-cells (van Ham et al., 2000). First, DO reduces class II-mediated 
antigen presentation as a whole, leading to a generalized diminished CD4+ response. 
Second, DO regulates the composition of the class II-mediated peptide repertoire that will 
determine the specificity of the B cell-induced immune response. Both modulatory actions of 
DO may increase the threshold for nonspecific CD4+ activation and may prevent 
autoimmune responses, both of which could be obvious evolutionary selection criteria. In 
this respect, it is interesting to note that DO-deficient mice have a normal functioning 
immune system, but show higher levels of serum immunoglobulins. This may indicate that 
the absence of DO leads to a more generalized immune activation.      
An association between HLA and autoimmune diabetes mellitus has been recognized for 
more than 20 years. The initial associations were found with the HLA class I serologically-
defined alleles B8 and B15. When the HLA-DR locus was defined, it was found that T1D 
associated more closely with the DR4 and DR3 serotypes than the linked B8 and B15. Later, 
it was determined that DR4 was a haplotype consisting of a family of distinct HLA-DR and 
–DQ molecules. This led to the conclusion that the DQB1 locus of HLA-DQ is highly 
associated with T1D. Recent technologies, which have allowed for genome-wide searches 
for linkage in humans to T1D, have verified that HLA is a gene locus involved in T1D and, 
in fact, HLA is the major locus. The strongest association within the HLA gene complex is to 
combinations of DQA1 and DQB1.  
Many studies have verified that DQB1*0302 is a strong susceptibility gene and that the 
heterozygous combination of DQA1*0301-DQB1*0302 on the HLA-DR4 haplotype and 
DQA1*0501-DQB1*0201 on the HLA-DR3 haplotype results in a synergistically increased 
risk of T1D (Table 1). DQA1*0301-DQB1*0302 is the most prevalent risk conferring 
haplotype in Caucasians detected in 74% of type 1 diabetes patients followed by 
DQA1*0501-DQB1*0201 detected in 52% of Caucasian patients (Sanjeevi et al., 1995).´ 
 
DQB1*0201     -     DQA1*0501     -     DRB1*0301 
 
DQB1*0302     -     DQA1*0301     -     DRB1*0401 
 
Table 1. Predisposition HLA haplotypes in T1D (marker IDDM1 of 6p21.3 locus). 
Also, there is agreement that DQB1*0602 allele, linked with DR2, is a strong protective gene 
(Kockum et al., 1993). The protective effect of DQB1*0602 is dominant to the susceptibility 
effects of DQB1*0302-DQA1*0301 and DQB1*0201-DQA1*0501 (Pugliese et al, 1995). A 
single copy of this DQB1*0602 allele is adequate to confer significant negative association. 
HLA-DQ genes are of primary importance but HLA-DR genes modify the risk conferred by 
HLA-DQ (Sanjeevi et al., 1996). The risk associated with an HLA genotype is defined by the 
particular combination of susceptible and protective alleles. The frequencies of 
predisposition alleles, DQB1*0302 and DQB1*0201, are usually increased, while frequency of 
protective DQB1*0602 allele is usually decreased. 
The categorization of T1D as an autoimmune disease is not ambiguous, with the presence of 
the predisposing HLA class II haplotypes, DRB1*04-DQB1*0302 and DRB1*03, in at least 
90% of cases and the presence of autoantibodies and, more recently, autoreactive, anti-islet 
www.intechopen.com
 
Type 1 Diabetes – Pathogenesis, Genetics and Immunotherapy 
 
616 
antigen-specific T-cells in the circulation of prediabetic individuals and of newly diagnosed 
and established cases (Todd, 2010). Transgenic mouse modeling (Nakayama et al., 2005; 
Mellanby et al., 2008) has provided direct support that it is the peptide-binding activity of 
the HLA class II molecules in antigen-presenting cells (APCs) for T lymphocyte peptide 
recognition that is the main mechanism of action of the DR and DQ molecules in T1D 
etiology. This is by far the major determinant of disease in the genome (Cucca et al., 2001; 
Zhang et al., 2008). In humans (and mice), susceptibility and resistance to T1D has been 
mapped to particular polymorphic peptide-binding pockets of the DQ molecule, pocket 9, 
and of DR, pockets 1 and 4 (and their mouse orthologs, IA and IE, respectively) (Cucca et al., 
2001; Suri et al., 2005). It remains a goal to identify molecules that modulate the function of 
these pockets and could be therapeutic. 
Class II molecules in APCs bind peptides from the currently identified autoantigens, 
preproinsulin (PPI), insulinoma-associated antigen 2 (I-A2), glutamic acid decarboxylase 
(GAD), and zinc transporter (ZnT8), and present these to CD4+ T-cell antigen receptors 
(TCRs) in the thymus and in the periphery, for example, in pancreatic lymph nodes and 
within the islets themselves (von Herrath, 2009). CD4+ T-cells provide help to CD8+ 
cytotoxic T-cells, which are the widely accepted most important killer of human islet beta 
cells in T1D autoimmunity (Skowera et al., 2008; Willcox et al., 2009). 
Recent fine mapping of the extended MHC region, 8 Mb of chromosome 6p21, which was 
made possible by the development of high-throughput, dense, and genome-wide SNP 
genotyping (GWAS), has confirmed that the major susceptibility, and resistance, to T1D 
does indeed map to the HLA class II region of the MHC (Nejentsev et al., 2007; Howson et 
al., 2009). 
This long-awaited comprehensive genetic mapping also showed that T1D susceptibility is 
modified, however, by lesser but still important effects of the specific allotypes of the 
equally polymorphic HLA class I molecules, HLA-B and HLA-A (Nejentsev et al., 2007; 
Howson et al., 2009). These molecules present peptides to cytotoxic CD8+ T-cells and are 
expressed strongly in the pancreatic insulin-producing beta cells (von Herrath, 2009). These 
recent HLA class I associations with T1D and additional histological evidence (Willcox et al., 
2009) help secure a central role for CD8+ T-cells and their helpers, CD4+ T-cells and APCs, 
in T1D etiology. 
4. Non-HLA genes 
This central role for APC-peptide-T-cell interaction in T1D is emphasized. However, the 
etiopatogenesis of disease is completely dependent not only on the environment, but also on 
the alleles of multiple genes across the genome (Wicker et al., 2005), which products are 
involved in following immunological reactions. The specific MHC/peptide-TCR interaction, 
although necessary, is not sufficient to fully activate the T-cell. A second signal is required; 
otherwise the T-cell will become unresponsive. This second signal, also referred to as co-
stimulation, is of crucial importance. The most potent co-stimulatory molecules known are 
B7s, which are Ig superfamily molecules, including B7-1 (CD80) and B7-2 (CD86). B7s exist 
as homodimers on the cell surface. These proteins are constitutively expressed on dendritic 
cells, but can be upregulated on monocytes, B-cells and probably other APCs. They are the 
ligands for other Ig superfamily molecules, CD28 and its homologue CTLA-4 (CD152) – 
which is expressed after T-cell activation. CD28 is the main co-stimulatory ligand expressed 
on naïve T-cells. CD28 stimulation has been shown to prolong and augment the production 
www.intechopen.com
 
Genetics of Type 1 Diabetes 
 
617 
of IL-2 and other cytokines, and is probably important in preventing the induction of 
tolerance. CTLA-4, the alternative ligand for B7, is an inhibitory receptor limiting T-cell 
activation, resulting in less IL-2 production. Thus CD28, constitutively expressed, initially 
interacts with B7, leading to T-cell activation, but once this has peaked, the upregulation of 
CTLA-4 with its higher affinity limits the degree of activation, as available B7 will interact 
with CTLA-4. 
Apart from the cell-surface interactions, cytokines, acting locally, are also involved in T-cell 
activation. IL-2 is responsible for promoting cell division in a resting T-cell. Triggering of the 
TCR along with co-receptors results in IL-2 synthesis by the T-cell itself. This binds to low-
affinity IL-2 receptors on the T-cell surface that consist of two chains, beta and gamma. TCR 
triggering also results in expression of the alpha-chain of the IL-2 receptor, which, in 
conjugation with the other two chains, results in a high-affinity receptor. The alpha chain 
together with the beta chain binds IL-2, while the gamma chain signals to the cell. There is a 
transient production of IL-2 for 1-2 days. Other cytokines may also contribute to T-cell 
proliferation, and their relative representation in microenvironment determines 
development of certain T-cell subtypes. It is assumed that impairment of the balance 
between Th1 and Treg cells participates in etiopatogenesis of autoimmune diabetes. The 
transient expression of the high affinity IL-2 receptor for about 1 week after stimulation of 
the T-cell, together with the induction of CTLA-4 helps limit T-cell division. (In the absence 
of positive signals, the T-cells will start to die by programmed cell death, apoptosis.) 
Based upon current analyses of completed genome screens, these non-HLA region genes 
may contribute relatively smaller (but significant) increments in genetic risk on an 
individual basis (Invernizzi & Gershwin, 2009). For example, PTPN22, INS, and IL2RA loci, 
which are the only other generally accepted genetic contributors to T1D risk, have a relative 
risk 3.9, 3.5 and 2.5, respectively. Other locus-specific effects range from 1.1-1.9.  
In T1D, there are currently identified 52 non-HLA regions. For 15 of them, the most likely 
causal gene in the locus was defined, as supported by current functional evidence (Todd, 
2010). Summary of candidate causal genes is in the Table 2. They are listed according to 
decreased relative risk. Further, there are currently identified 423 genes in the immediate 
high-association interval and 790 genes in the > 1 Mb regions. In addition, there are 167 and 
433 non-protein-coding sequences in these two categories of regions, and these could well 
have altered functions owing to genome polymorphism.   
Perhaps the most replicated and broadly relevant of these associations is with the intracellular 
protein tyrosine phosphatase non receptor 22 (PTPN22). The gene for PTPN22 is located on 
chromosome 1p13.2. The initial association of PTPN22 with T1D was reported by Bottini et al., 
2004, who took a candidate gene approach and focused on a nonsynonymous amino acid 
polymorphism (R620W, substitution of tryptophan for arginine) that was judged likely to have 
functional correlates. This polymorphism corresponds to a single nucleotide substitution of 
thymin for cytosine at the position 1858 of DNA (C1858T). In an independent effort, Begowich 
et al., 2004, selected PTPN22 as part of a limited genome-wide screen of likely functional 
variants in several thousand candidate genes, informed in part by previous linkage results. 
This led to the association of PTPN22 with RA. Both associations have now been widely 
replicated, and the PTPN22 associations with these and several other autoimmune diseases are 
among the most robust in the literature. For RA and T1D the PTPN22 620W allele confers a 
nearly two-fold risk for disease, with odds ratios in the range of 3-4 for homozygous 
individuals. Thus, in terms of strength of association, PTPN22 is second in importance only to 
the HLA for these two diseases. 
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in immune system 
PTPN22    1p13.2 3,9 TCR and BCR signaling 
INS IDDM2 11p15.5 3,5 Autoantigen 
IL2RA IDDM10 10p15.1 2,5 T-cell and Treg homeostasis 
CCR5    3p21.31 1,9 Th1-cell signaling 
SH2B3  12q24.12 1,7 Intracellular adaptor protein 
PTPN2  18p11.21 1,7 Negative regulation of T-cells 
IL10    1q32.1 1,5 Inhibition of Th1-cells 
CTLA-4 IDDM12   2q33.2 1,5 T-cell costimulatory inhibition 
TLR7/TLR8    Xp22.2 1,4 Receptors for viral RNAs 
IFIH1    2q24.2 1,4 Receptor for viral RNAs 
IL2    4q27 1,3 T-cell and Treg homeostasis 
GLIS3    9p24.2 1,3 Autoantigen 
IKZF1    7p12.2 1,2 Lymphopoiesis regulation 
IL7RA    5p13.2 1,2 Memory T-cell homeostasis  
TAGAP IDDM5   6q25.3 1,2 T-cell activation 
IL18RAP    2q12.1 1,2 IFN-gamma induction  
CCR5 = cytokine-chemokine receptor 5 
CTLA-4 = cytotoxic T lymphocyte antigen 4 
GLIS3 = GLIS family zinc finger 3 
IFIH1 = interferon induced with helicase C domain 1 
IKZF1 = IKAROS family zinc finger 1 
IL2 = interleukin 2 
IL10 = interleukin 10 
IL2RA = interleukin 2 receptor alpha  
IL7R = interleukin 7 receptor  
IL18RAP = interleukin 18 receptor accessory protein 
INS = insulin 
PTPN22 = protein tyrosine phosphatase, non-receptor type 22  
PTPN2 = protein tyrosine phosphatase, non-receptor type 2  
SH2B3 = intracellular adaptor protein with PH and SH2 domains  
TAGAP = T-cell activation RhoGTPase activating protein  
TLR = Toll-like receptor 
Table 2. The most significant non-HLA predisposition markers with known function in T1D 
(listed according to decreased value of RR). 
The patterns of association between the PTPN22 620W allele and autoimmunity are 
instructive on many levels. First, PTPN22 was among the first and most convincing 
demonstrations that common susceptibility genes underlie diverse autoimmune 
phenotypes. In addition to T1D and RA, PTPN22 is associated with Graves’ disease (Velaga 
et al., 2004), Hashimoto thyroiditis (Criswell et al., 2005), myasthenia gravis (Vandiedonck et 
al., 2006), systemic sclerosis (Dieude et al., 2008), generalized vitiligo (LaBerge et al., 2008), 
Addison’s disease (Skinningsrud et al., 2008), and alopecia areata (Betz et al., 2008). 
Associations with juvenile idiopathic arthritis (JIA) and SLE have generally been weaker 
than for RA and T1D. Strikingly, there is no evidence of association with multiple sclerosis, 
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and the 620W allele actually appears to be protective for Crohn’s disease (Barrett et al., 
2008). These contrasting patterns of association are likely to reflect fundamental similarities 
and differences in the mechanisms underlying the pathogenesis of these disorders. In 
general, it appears that an important feature of the PTPN22-associated diseases is that they 
all have a prominent component of humoral autoimmunity. 
Knockout animals for Lyp (also known as PEP, the mouse ortholog of PTPN22) exhibit 
enhanced T-cell activation in combination with an increased production of antibodies 
(Hasegawa et al., 2004). This is consistent with the ability of PTPN22 to dephosphorylate Lck 
at the activating phosphotyrosine 394, leading to persistent phosphorylation and Lck 
activation in knockout animals. Lck is the tyrosine kinase of the Src family associated with 
CD4 and CD8. Yet somewhat surprisingly, the consequence of the 620W risk allele in 
humans is apparently a lower degree of T cell activation - an increased threshold for T-cell 
receptor signaling (Vang et al., 2005; Rieck et al., 2007). One clear biochemical consequence 
of the 620W polymorphism is to reduce the binding of PTPN22 with the intracellular kinase 
Csk (Bottini et al., 2004; Begovich et al., 2004). Indeed, amino acid position 620 of PTPN22 is 
located within one of several SH3 binding sites in the PTPN22 molecule. An important role 
of Csk is to inhibit Lck activity by phosphorylation of amino acid 505 of the Lck molecule 
(Vang et al., 2008). Whether this particular activity is affected by the 620W polymorphism in 
PTPN22 is unclear. Bottini and coworkers have proposed a model for interactions among 
Lck, PTPN22, and Csk that may explain the elevation of thresholds for TCR signaling, with 
the overall implication that reduced, rather than elevated, T-cell triggering may be part of 
the phenotypic predisposition to autoimmunity. A similar tendency to increased thresholds 
for receptor triggering has also been reported in B-cells (Rieck et al., 2007). 
A second intracellular protein tyrosine phosphatase non receptor 2 (PTPN2) encoded on 
chromosome 18p11.21 has also been associated with human autoimmunity; convincing 
associations have been reported for T1D (Todd et al., 2007) and Crohn’s disease (Wellcome 
Trust Case Control Consortium, 2007; Barrett et al., 2008), with odds ratios in the range of 
1.3. PTPN2 is ubiquitously expressed and is clearly involved in immune function. PTPN2-
knockout animals exhibit a fatal inflammatory wasting syndrome (Pao et al., 2007), with 
accompanying abnormalities in multiple cell types. PTPN2 appears to have a negative 
regulatory role on IL-2R signaling in T-cells, consistent with the fact that Janus family 
kinases 1 and 3 (Jak1 and Jak3) are among its substrates (Simoncic et al., 2002). 
The insulin (INS) gene is located on chromosome 11p15.5. The immune-mediated process 
leading to development of T1D is highly specific to pancreatic beta cells. The insulin gene, 
therefore, is a plausible candidate susceptibility locus since preproinsulin has emerged as 
the most important autoantigen in childhood-onset T1D (Skowera et al., 2008).   
Mutations of INS cause a rare form of diabetes that is similar to MODY (Maturity Onset 
Diabetes in the Young). Other variations of the insulin gene (variable number tandem 
repeats and SNPs) play a role in susceptibility to T1D and T2D. The polymorphism in the 
insulin minisatellite or variable number of tandem repeats (INS VNTR) are associated with 
the risk of diabetes and influence thymic insulin messenger RNA (Bell et al., 1984; Bennett et 
al., 1995, 1996). It is located 596bp upstream of the insulin gene translation initiation site and 
it is composed of a variable number of tandem repeats of 14-15bp in length based on the 
consensus sequence 5`-ACAGGGGTGTGGGG-3` (Bell et al., 1982). There are three main 
types of INS VNTR defined by their size: class I (26-63 repeats), class II (approximately 80 
repeats) and class III (140-200 repeats). Each of them can be further divided based on the 
number of repeats and sequence. In white European population the minisatellite displays a 
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bimodal allele size distribution with class I alleles and class III alleles at frequencies of 70% 
and 30%. Class II alleles are rare in white European population. Allelic variation in size of 
the insulin VNTR correlates with the expression of insulin in the pancreas and thymus and 
with placental expression of insulin growth factor-2 gene (IGF-2), which is downstream 
from the insulin gene (Moore et al., 2001). 
Homozygosity for class I alleles is generally associated with high risk for diabetes, whereas 
class III alleles confer dominant protection. Class III alleles are associated with higher 
expression of insulin messenger RNA within the thymus and insulin with thymic 
transcription activity correlate inversely with susceptibility to diabetes in humans (Pugliese 
et al., 1997; Vafiadis et al., 1997). These findings support hypothesis that genetically 
determined differences in the expression of self antigens in the thymus could influence 
susceptibility to autoimmunity. High concentration of thymic insulin might lead to negative 
selection (deletion) of autoreactive T-cells bearing a TCR that is directed against self 
antigens and thus to the development of tolerance.     
The gene encoding the high-affinity alpha chain of the three-chain IL-2 receptor (IL2RA, 
CD25) on chromosome 10p15.1 is also strongly associated with T1D with evidence for at 
least two distinct causal variants (Dendrou et al., 2009). Correlations, first with soluble CD25 
in serum and plasma (Lowe et al., 2007), and then with mRNA and with CD25 surface 
expression (Dendrou et al., 2009), indicate unequivocally that IL2RA is a causal gene in this 
chromosome region. T1D-predisposing alleles of SNPs in intron 1 and the 5’region of the 
gene lower transcription, which results in lower amounts of CD25 on the surface of memory 
CD4+ T-cells and also in number of CD25+ naive CD4+ T-cells. One of the notable results to 
come out of this large-scale clinical study was that the expression of CD25 on memory T-
cells was highly repeatable within the same person across several months and, thus, 
strongly heritable, indicating that here is an immunophenotype that is hard-wired into the 
human genome. For the 1% of the British population that have the most protective IL2RA 
genotype and most CD25 on these memory cells, there is considerable protection from T1D. 
Memory CD4+ T-cells with more CD25 on their surface secrete more IL-2 on stimulation, 
and hence, it is possible that T-cells are a source for IL-2, which could promote Treg cell 
function. From the results in T1D for the IL-2 and IL2R genes (there is an evidence for the 
exon 1 common synonymous SNP of IL2 and the SNP of IL2RB associations with T1D), one 
can ask the question: with such fundamental molecules being altered in the immune system, 
both of which are essential for immune tolerance, why are several immune diseases not 
associated with these variants? Answer can be simple: The balance between the functions of 
T effector and Treg cells appears to be important in human T1D (Lawson et al., 2008; Long et 
al., 2009, 2010).  
Moreover, the cytokine-chemokine receptor 5 (CCR5) gene on chromosome 3p21.31, which 
has a naturally occurring, albeit rare (1% in populations), functionally disruptive variant, 
delta32 (the 32 base pair deletion), is associated with protection from T1D, RA, and celiac 
disease (Smyth et al., 2008), indicating the importance of chemokines and T-cell trafficking 
in T1D. 
An exciting example of the rapid gain in knowledge is the intracellular adaptor protein 
with PH and SH2 domains (SH2B3) gene on chromosome 12q24.12. This gene was first 
associated with T1D (Todd et al., 2007), in which a nonsynonymous SNP, corresponding to a 
nonsynonymous amino acid polymorphism (R262W, substitution of tryptophan for 
arginine), was the most associated marker. The 262W allele is the nonancestral allele altering 
the sequence of a predicted functional pleckstrin homology domain, suggestive that this 
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could be a causal SNP and gene. Subsequently, the same variant was associated with celiac 
disease (Hunt et al., 2008) and, most recently, with platelet count and cardiovascular disease 
(Soranzo et al., 2009). The latter study also focused on the R262W polymorphism and 
showed that the 262W allele lies on a very long extended conserved haplotype for which 
they provided evidence for very recent selection in European populations, presumably to 
help provide resistance to a pathogen(s). SH2B3 encodes Lnk, an important negative 
regulator of cell-signalling events from a number of receptors, including the TCR and MPL, 
the latter of which is the receptor for thrombopoietin on platelets. In general, Lnk negatively 
regulates lymphopoiesis and early hematopoiesis. It functions in responses controlled by 
cell adhesion and in crosstalk between integrin- and cytokine-mediated signalling (Takaki, 
2008). The lnk-deficiency results in enhanced production of B-cells, and expansion as well as 
enhanced function of hematopoietic stem cells. These facts support the hypothesis that 
SH2B3 is the disease-causal gene in this chromosomal region. 
Another candidate gene for T1D and other autoimmune diseases is located on chromosome 
2q33.2 and encodes the T-cell costimulatory receptor, cytotoxic T lymphocyte antigen 4 
(CTLA-4, CD152). In addition to T1D (Ueda et al., 2003), many human autoimmune diseases 
are associated with SNPs in the CTLA-4 gene, including Graves’ disease (Ueda et al., 2003), 
RA (Plenge et al., 2005), SLE (Barreto et al., 2004), and celiac disease (Smyth et al., 2008). 
Mutations or polymorphisms leading to altered activity of CTLA-4 are believed to play an 
important role in the risk for developing autoimmunity (Maier & Hafler, 2009). The effect of 
CTLA-4 gene seems to be independent of the HLA alleles or the insulin VNTR risk genotype 
(van der Auwera et al., 1997). There is a microsatellite marker in the 3’UTR of the CTLA-4 
sequence, and several point polymorphisms have been detected at CTLA-4. A large-scale 
fine mapping and sequencing study has previously pinpointed the causal variant for T1D 
and Graves’ disease to a SNP called CT60, which is located in the 3’ untranslated region 
(UTR) of CTLA-4 near the polyA site. Such large-scale fine mapping studies are warranted 
for all other autoimmune diseases that have previously associated with variants at CTLA-4. 
Interestingly, some evidence has also been produced to suggest that CTLA-4 
polymorphisms may influence gene expression. CTLA-4 functions as a potent negative T-
cell regulator. Deficiency of CTLA-4 in mice leads to a lymphoproliferative disorder, causing 
death within 4 weeks of birth. More recently, its protein product has been shown to have an 
essential and specific role in Treg cell function in mice (Wing et al., 2008). One outstanding 
question is the role and function of the isoform of CTLA-4 that is missing the 
transmembrane domain (encoded by exon 3), referred to as soluble CTLA-4, and which is 
presumed to be secreted. The genetic analyses and correlation of CTLA-4 gene haplotypes 
with messenger RNA levels suggest that it is a reduction in the amount of soluble CTLA-4 
that is responsible for the increased susceptibility to T1D in T-cells, including Treg cells 
(Atabani et al., 2005). Ueda et al., 2003, suggested that the disease susceptible genotype at 
the CT60 SNP (the G allele) influences the relative splicing efficiency and production of 
soluble CTLA-4 (sCTLA-4) versus full-length CTLA-4 (flCTLA-4) mRNA. In fact, GG 
homozygote individuals at CT60 (disease susceptible genotype) had half the levels of 
sCTLA-4 when normalized to flCTLA-4 compared with AA homozygote individuals at 
CT60. Indeed, the 3’ UTR of CTLA-4 has been shown to regulate the mRNA steady-state 
levels of CTLA-4 and sequences in the 3’ UTR regulate CTLA-4 mRNA stability and in vitro 
translation efficiency (Malquori et al., 2008). Another study has shown that the relative 
responsiveness of naive (CD4+ CD45RAhigh) versus memory (CD4+ CD45RAlow) T-cell 
subsets to TCR signaling was altered in healthy donors with the susceptible G allele 
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compared to healthy donors with the protective A allele at CT60 (Maier et al., 2007). The 
CT60 SNP, in combination with autoantibody measurement, has also allowed the 
identification of a subgroup of T1D subjects; the presence of autoantibodies against thyroid 
peroxidases (TPOAb) not only increases risk of T1D, but also results in an earlier age of 
onset of disease. Individuals with the G allele or GG genotype exhibit an almost twofold 
increased risk of having both T1D and TPOAbs (Howson et al., 2007). It is of interest to note 
that the CTLA4 association at CT60 with RA is also enhanced in subjects with RA who are 
seropositive for anti-citrulline antibodies (Plenge et al., 2005).      
CTLA-4 is also important in preventing autoimmunity in a major mouse model of T1D, the 
non-obese diabetic (NOD) mouse. In addition to the full-length and soluble isoforms, a 
ligand-independent form of CTLA-4 (liCTLA-4) was discovered in mouse (Wicker et al., 
2004). The mRNA for liCTLA-4 lacks exon 2 and therefore encodes a molecule lacking the 
CD80/CD86 ligand binding domain. In the NOD mouse, it is the liCTLA-4 isoform that is 
differentially regulated by susceptible and protective CTLA-4 alleles. This genotype-
dependent expression of the liCTLA-4 isoform is most likely because of a synonymous SNP 
in an exon splicing silencer motif located in exon 2. The liCTLA-4 isoform was shown to 
strongly inhibit T-cell responses by binding and dephosporylating the TCR chain and 
emerged as a more potent negative T-cell regulator than flCTLA-4 in terms of proliferation 
and cytokine secretion (Vijayakrishnan et al., 2004). As reduced expression of sCTLA-4 and 
liCTLA-4 isoforms is associated with increased disease susceptibility in humans and the 
NOD mouse model, respectively, and liCTLA-4 has been shown to be a potent inhibitor of 
T-cell activation and/or expansion, human sCTLA-4 may have a similar role. These data 
suggest that autoimmune-susceptible alleles may directly predispose to loss or reduced 
levels of self-tolerance.        
Concerning virus participation in disease etiopatogenesis, encouraging candidates for T1D 
are the toll like receptor 7 - toll like receptor 8 (TLR7-TLR8) region of chromosome Xp22.2 
that encodes intracellular receptors for viral RNAs and for DNA and RNA from apoptotic 
cells, and the interferon induced with helicase C domain 1 (IFIH1) gene on chromosome 
2q24.2 that also encodes intracellular receptor known to recognise viral RNA and mediate 
the innate immune response. IFIH1 is also termed as melanoma differentiation-associated 
protein 5 (MDA5). IFIH1 is causal in T1D based on the protective associations of four rare 
variants, where the derived alleles are predicted to reduce gene expression or function 
(Nejentsev et al., 2009). Most intriguingly, among the viruses detected by IFIH1 are viruses 
from the picornavirus family, of which enterovirus is a member. Enteroviruses, of which 
coxsackie virus is a member, are one of the most common types of viruses reported to be 
associated with T1D (Dotta et al., 2007). Binding of viral RNA to IFIH1 triggers the 
production of the type 1 interferons (alpha and beta), which could, in a highly plausible 
scenario, enhance anti-beta cell CD8+ cytotoxic T lymphocyte activity in islets via HLA class 
I upregulation on beta cells, and direct effects on CD4+ and CD8+ T-cells (Devendra & 
Eisenbarth, 2004; Li et al., 2008; von Herrath, 2009). The genetic results suggest that a variety 
of virus infections could, via increased type 1 interferon levels, enhance susceptibility to 
autoimmune beta-cell destruction and T1D, provided that susceptibility alleles at other loci 
are present. Seasonal differences in viral infections, combined with other seasonal effects 
such as reduced vitamin D levels in more northern countries during the winter months 
(Hyppönen & Power, 2007; Svoren et al., 2009), could help explain the well-established 
seasonality of T1D diagnosis itself.  
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The gene encoding the GLI-similar 3 (GLIS3) protein on chromosome 9p24.2 is also 
associated with T1D. GLIS3 protein belongs to a subfamily of the Krüppel-like zinc finger 
transcription factors. GLIS3 plays a key role in pancreatic development, particularly in the 
generation of beta-cells and in the regulation of insulin gene expression. It could be an 
autoantigen in T1D for which polymorphism in or near the gene alters its expression in beta-
cells, as found for insulin. Mutations in GLIS3 have been implicated in a syndrome 
characterized by neonatal diabetes and congenital hypothyroidism (Senée et al., 2006) and in 
some patients accompanied by polycystic kidney disease, glaucoma and liver fibrosis. In 
addition, the GLIS3 gene has been associated with fasting glucose levels and type 2 diabetes 
(T2D) susceptibility (Dupuis et al., 2010). Therefore, this would be the first convincing 
example of a gene predisposing to both T1D and T2D. Otherwise, T1D and T2D are 
genetically and, therefore, etiologically distinct (Rafiq et al., 2008; Raj et al., 2009). 
The gene on chromosome 7p12.2 encoding the IKAROS family zinc finger 1 (IKZF1) 
protein, that is an essential regulator of lymphopoiesis and immune homeostasis, has been 
implicated in the development of childhood acute lymphoblastic leukemia. The major IKZF1 
genotype conferring susceptibility to this leukemia has been shown to protect against T1D 
(Swalford et al., 2011). This finding strengthens the link between autoimmunity and 
lymphoid cancers. 
The gene encoding the T-cell activation RhoGTPase activating protein (TAGAP) on 
chromosome 6q25.3 is associated not only with T1D, but also with RA, celiac and Crohn’s 
diseases. The TAGAP minor allele confers protection against RA, similar to previous reports 
of T1D but contrasting with celiac and Crohn’s diseases in which the minor allele is 
associated with risk (Eyre et al., 2010). TAGAP is transiently expressed in activated T-cells, 
suggesting that it may have a role in immune regulation. 
Exploring the genetic overlap between related diseases may reveal key common 
autoimmunity-inflammatory pathways, and that further combinations of more disease-
specific variation at HLA and non-HLA genes, in interaction with epigenetic and 
environmental factors, determine the final clinical outcomes (Table 3).  
It is interesting to note that the shared genetic predisposition between T1D and celiac 
disease (Smyth et al., 2008) supports further evaluation of the hypothesis that gut microflora 
dysbalance and gluten consumption might be an environmental factor in T1D leading to the 
alteration of the function of the gut immune system and its relationship with the pancreatic 
immune system (Turley et al., 2005; Vaarala et al., 2008; Wen et al., 2008). Conversely, genes 
classified as autoimmunity genes, because they are associated with T1D, contribute to celiac 
disease. However, there are some causal alleles with the effects in the opposite direction and 
some distinct differences in genetic susceptibility between the two diseases. There is also a 
certain significant overlap between T1D and RA that is much greater than between celiac 
disease and RA (Eyre et al., 2010). These data suggest that a common etiology may exist 
between T1D and celiac disease, but a common pathogenesis may exist between T1D and 
RA.  
Shared causal variants among autoimmune diseases could suggest therapeutic targets 
applicable to more than one disease. However, the susceptibility loci unique to a particular 
disease are also of interest; differences may reflect genuine specificity between the diseases 
and may influence what determines the particular autoimmune phenotype that may have 
also clinical application. 
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Locus Other autoimmune diseases 
HLA almost all autoimmune diseases 
PTPN22 
RA, Graves’ disease, Hashimoto thyroiditis, myasthenia gravis, 
systemic sclerosis, generalized vitiligo, Addison’s disease, 
alopecia areata, 
weak association with JIA and SLE, 
opposite effect (protection) in Crohn’s disease, 
no association with celiac disease and multiple sclerosis 
IL2RA multiple sclerosis, but no association with celiac disease  
CCR5 RA, celiac disease 
SH2B3 celiac disease 
PTPN2 celiac disease, Crohn’s disease 
CTLA4 Graves’ disease, RA, SLE, celiac disease, Crohn’s disease 
TLR7/TLR8 celiac disease 
IL7RA multiple sclerosis 
TAGAP RA, opposite effect (predisposition) in celiac disease, Crohn’s disease 
IL18RAP opposite effect (predisposition) in celiac disease, Crohn’s disease 
JIA = juvenile idiopathic arthritis 
RA = rheumatic arthritis 
SLE = systemic lupus erythematosus 
Table 3. Predisposition loci in T1D associated with other autoimmune diseases. 
5. Epigenetics  
The other area that is relevant is the role of epigenetics (Wang et al., 2009; MacFarlane et al., 
2009; Javierre et al., 2010), which provides a molecular bridge between genes and environment 
(Waterland et al., 2006; MacFarlane et al., 2009). Stochastic early epigenetic imprinting that can 
alter gene expression as well as environmentally-induced epigenetic changes (Waterland et al., 
2006; MacFarlane et al., 2009; Tobi et al., 2009), including the aging process itself (Rakyan et al., 
2010), could help account for the discordance of monozygotic twins for disease (Kaminsky et 
al., 2009). Recently, the first parentally imprinted susceptibility region has been reported, 
involving the DLK1-MEG3 locus on chromosome 14q32, in which expression of the maternal 
haplotype of these genes is suppressed by epigenetic mechanisms such that the risk of T1D at 
this locus is transmitted from fathers only (Wallace et al., 2010). Therefore, going forward, it 
will be necessary to combine studies correlating disease-associated SNP alleles and haplotypes 
with gene expression and splicing, with measurement of their methylation status (Todd, 2010). 
T1D genes are already known to have differentially-methylated regions that affect their 
expression, namely INS, IL2, and IL10. 
6. Acknowledgments 
This survey was funded by the Research design of the Ministry of Education and Youth of 
Czech Republic: Identification code: MSM 0021620814: Prevention, diagnostics and therapy 
of diabetes mellitus, metabolic and endocrine damage of organism.  
www.intechopen.com
 




Atabani SF, Thio CL, Divanovic S et al. (2005). Association of CTLA4 polymorphism with 
regulatory T cell frequency. European Journal of Immunology, 35, 2157-2162. 
Barreto M, Santos E, Ferreira R et al. (2004). Evidence for CTLA4 as a susceptibility gene for 
systemic lupus erythematosus. European Journal of Human Genetics, 12, 620-626. 
Barrett JC, Hansoul S, Nicolae DL et al. (2008). Genome-wide association defines more than 
30 distinct susceptibility loci for Crohn’s disease. Nature Genetics, 40, 955-962.  
Begovich AB, Carlton VE, Honigberg LA et al. (2004). A missense single-nucleotide 
polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is 
associated with rheumatoid arthritis. American Journal of Human Genetics, 75, 330-
337. 
Bell GI, Selby MJ, Rutter WJ (1982). The highly polymorphic region near the human insulin 
gene is composed of simple tandemly repeating sequences. Nature, 295, 31-35. 
Bell GI, Horita S, Karam JH (1984). A polymorphic locus near the human insulin gene is 
associated with insulin-dependent diabetes mellitus. Diabetes, 33, 176-183. 
Bennett ST, Lucassen AM, Gough SC et al. (1995). Susceptibility to human type 1 diabetes at 
IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite 
locus. Nature Genetics, 9, 284-292. 
Bennett ST, Wilson AJ, Cucca F et al. (1996). IDDM2-VNTR-encoded susceptibility to type 1 
diabetes: dominant protection and parental transmission of alleles of the insulin 
gene-linked minisatellite locus. Journal of Autoimmunity, 9, 415-421. 
Betz RC, Konig K, Flaquer A et al. (2008). The R620W polymorphism in PTPN22 confers 
general susceptibility for the development of alopecia areata. British Journal of 
Dermatology, 158, 389-391. 
Bottini N, Musumeci L, Alonso A et al. (2004). A functional variant of lymphoid tyrosine 
phosphatase is associated with type I diabetes. Nature Genetics, 36, 337-338.   
Chapman JM, Cooper JD, Todd JA et al. (2003). Detecting disease associations due to linkage 
disequilibrium using haplotype tags: a class of tests and the determinants of 
statistical power. Human Heredity, 56, 18-31. 
Criswell LA, Pfeiffer KA, Lum RF et al. (2005). Analysis of families in the multiple 
autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W 
allele associates with multiple autoimmune phenotypes. American Journal of Human 
Genetics, 76, 561-571. 
Cucca F, Lampis R, Congia M et al. (2001). A correlation between the relative predisposition 
of MHC class II alleles to type 1 diabetes and the structure of their proteins. Human 
Molecular Genetics, 10, 2025-2037. 
Dendrou CA, Plagnoi V, Fung E et al. (2009). Cell-specific protein phenotypes for the 
autoimmune locus IL2RA using a genotype-selectable human bioresource. Nature 
Genetics, 41, 1011-1015. 
Devendra D, Eisenbarth GS (2004). Interferon alpha – a potential link in the pathogenesis of 
viral-induced type 1 diabetes and autoimmunity. Clinical Immunology, 111, 225-233. 
Dieude P, Guedj M, Wipff J et al. (2008). The PTPN22 620W allele confers susceptibility to 
systemic sclerosis: findings of a large case-control study of European Caucasians 
and a meta-analysis. Arthritis and Rheumatism, 58, 2183-2188. 
www.intechopen.com
 
Type 1 Diabetes – Pathogenesis, Genetics and Immunotherapy 
 
626 
Dotta F, Censini S, van Halteren AG et al. (2007). Coxsackie B4 virus infection of beta cells 
and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proceedings of 
the National Academy of Sciences of the U.S.A., 104, 5115-5120. 
Downes K, Pekalski M, Angus KL et al. (2010). Reduced expression of IFIH1 is protective for 
type 1 diabetes. PLoS ONE, 5, e12646. 
Dupuis J, Langenberg C, Prokopenko I et al. (2010). New genetic loci implicated in fasting 
glucose homeostasis and their impact on type 2 diabetes risk. Nature Genetics, 42, 
105-116. 
Eyre S, Hinks A, Bowes J et al. (2010). Overlapping genetic susceptibility variants between 
three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac 
disease. Arthritis Research & Therapy, 12, R175.  
Frazer KA, Ballinger DG, Cox DR et al. (2007). A second generation human haplotype map 
of over 3.1 million SNPs. Nature, 449, 851-861. 
Gregersen PK, Olsson LM (2009). Recent advances in the genetics of autoimmune disease. 
Annual Review of Immunology, 27, 363-391. 
Hasegawa K, Martin F, Huang G et al. (2004). PEST domain-enriched tyrosine phosphatase 
(PEP) regulation of effector/memory T cells. Science, 303, 685-689.  
Howson JM, Dunger DB, Nutland S et al. (2007). A type 1 diabetes sub-group with a female 
bias is characterized by failure in tolerance to thyroid peroxidase at an early age 
and a strong association with the cytotoxic T-lymphocyte-associated antigen-4 
gene. Diabetologia, 50, 741-746. 
Howson JM, Walker NM, Clayton D et al. (2009). Confirmation of HLA class II independent 
type 1 diabetes associations in the major histocompatibility complex including 
HLA-B and HLA-A. Diabetes, Obesity & Metabolism, 11 (Suppl.1), 31-45. 
Hunt KA, Zhernakova A, Turner G et al. (2008). Newly identified genetic risk variants for 
celiac disease related to the immune response. Nature Genetics, 40, 395-402. 
Hyppőnen E, Power C (2007). Hypovitaminosis D in British adults at age 45y: Nationwide 
cohort study of dietary and lifestyle predictors. American Journal of Clinical 
Nutrition, 85, 860-868.  
Iles MM (2008). What can genome-wide association studies tell us about the genetics of 
common disease? PLoS Genet, 4, e33. 
Invernizzi P, Gershwin ME (2009). The genetics of human autoimmune disease. Journal of 
Autoimmunity, 33, 290-299. 
Ioannidis JP, Ntzani EE, Trikalinos TA et al. (2001). Replication validity of genetic 
association studies. Nature Genetics, 29, 306-309.   
Javierre BM, Fernandez AF, Richter J et al. (2010). Changes in the pattern of DNA 
methylation associate with twin discordance in systemic lupus erythematosus. 
Genome Research, 20, 170-179. 
Kaminsky ZA, Tang T, Wang SC et al. (2009). DNA methylation profiles in monozygotic and 
dizygotic twins. Nature Genetics, 41, 240-245. 
Kang HS, ZeRuth G, Lichti-Kaiser K et al. (2010). Gli-similar (Glis) Krüppel-like zinc finger 
proteins: insights into their physiological functions and critical roles in neonatal 
diabetes and cystic renal disease. Histology and Histopathology, 25, 1481-1496.  
Kockum I, Wassmuth R, Holmberg E et al. (1993). HLA-DQ primarily confers protection and 
HLA-DR susceptibility in type I (insulin-dependent) diabetes studied in 
www.intechopen.com
 
Genetics of Type 1 Diabetes 
 
627 
population-based affected families and controls. American Journal of Human Genetics, 
53, 150-167. 
LaBerge GS, Bennett DC, Fain PR et al. (2008). PTPN22 is genetically associated with risk of 
generalized vitiligo, but CTLA4 is not. Journal of Investigative Dermatology, 128, 1757-
1762. 
Lawson JM, Tremble J, Dayan C et al. (2008). Increased resistance to CD4+CD25hi 
regulatory T cell-mediated suppression in patients with type 1 diabetes. Clinical and 
Experimental Immunology, 154, 353-359. 
Li Q, Xu B, Michie SA et al. (2008). Interferon-alpha initiates type 1 diabetes in nonobese 
diabetic mice. Proceedings of the National Academy of Sciences of the U.S.A., 105, 12439-
12444. 
Long SA, Walker MR, Rieck M et al. (2009). Functional islet-specific Treg can be generated 
from CD4+CD25- T cells of healthy and type 1 diabetic subjects. European Journal of 
Immunology, 39, 612-620. 
Long SA, Cerosaletti K, Bollyky PL et al. (2010). Defects in IL-2R signaling contribute to 
diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells 
of type 1 diabetic subjects. Diabetes, 59, 407-415.    
Lowe CE, Cooper JD, Brusko T et al. (2007). Large-scale genetic fine mapping and genotype-
phenotype associations implicate polymorphism in the IL2RA region in type 1 
diabetes. Nature Genetics, 39, 1074-1082. 
MacFarlane AJ, Strom A, Scott FW (2009). Epigenetics: Deciphering how environmental 
factors may modify autoimmune type 1 diabetes. Mammalian Genome, 20, 624-632. 
Maier LM, Anderson DE, De Jager PL et al. (2007). Allelic variant in CTLA4 alters T cell 
phosphorylation patterns. Proceedings of the National Academy of Sciences of the 
U.S.A., 104, 18607-18612. 
Maier LM, Hafler DA (2009). Autoimmunity risk alleles in costimulation pathways. 
Immunological Reviews, 229, 322-336. 
Malquori L, Carsetti L, Ruberti G (2008). The 3’ UTR of the human CTLA4 mRNA can 
regulate mRNA stability and translational efficiency. Biochimica et Biophysica Acta, 
1779, 60-65. 
Mellanby RJ, Phillips JM, Parish NM et al. (2008). Both central and peripheral tolerance 
mechanisms play roles in diabetes prevention in NOD-E transgenic mice. 
Autoimmunity, 41, 383-394.  
Moore GE, Abu-Amero SN, Bell G et al. (2001). Evidence that insulin is imprinted in the 
human yolk sac. Diabetes, 50, 199-203. 
Mungall AJ, Palmer SA, Sims SK et al. (2003). The DNA sequence and analysis of human 
chromosome 6. Nature, 425, 805-811. 
Nakayama M, Abiru N, Moriyama H et al. (2005). Prime role for an insulin epitope in the 
development of type 1 diabetes in NOD mice. Nature, 435, 220-223. 
Nejentsev S, Howson JM, Walker NM et al. (2007). Localization of type 1 diabetes 
susceptibility to the MHC class I genes HLA-B and HLA-A. Nature, 450, 887-892.   
Nejentsev S, Walker N, Riches D et al. (2009). Rare variants of IFIH1, a gene implicated in 
antiviral responses, protect against type 1 diabetes. Science, 324, 387-389. 
Pao LI, Badour K, Siminovitch KA et al. (2007). Nonreceptor protein-tyrosine phosphatases 
in immune cell signaling. Annual Review of Immunology, 25, 473-523. 
www.intechopen.com
 
Type 1 Diabetes – Pathogenesis, Genetics and Immunotherapy 
 
628 
Plenge RM, Padyukov L, Remmers EF et al. (2005). Replication of putative candidate-gene 
associations with rheumatoid arthritis in >4,000 samples from North America and 
Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. American 
Journal of Human Genetics, 77, 1044-1060.  
Pugliese A, Gianani R, Moromisato R et al. (1995). HLA-DQB1*0602 is associated with 
dominant protection from diabetes even among islet cell antibody-positive first-
degree relatives of patients with IDDM. Diabetes, 44, 608-613. 
Pugliese A, Zeller M, Fernandez A et al. (1997). The insulin gene is transcribed in the human 
thymus and transcription levels correlated with allelic variation at the INS VNTR-
IDDM2 susceptibility locus for type 1 diabetes. Nature Genetics, 15, 293-297. 
Rafiq S, Melzer D, Weedon MN et al. (2008). Gene variants influencing measures of 
inflammation or predisposing to autoimmune and inflammatory diseases are not 
associated with the risk of type 2 diabetes. Diabetologia, 51, 2205-2213. 
Raj SM, Howson JM, Walker NM et al. (2009). No association of multiple type 2 diabetes loci 
with type 1 diabetes. Diabetologia, 52, 2109-2116. 
Rakyan VK, Down TA, Maslau S et al. (2010). Human aging-associated DNA 
hypermethylation occurs preferentially at bivalent chromatin domains. Genome 
Research, 20, 434-439. 
Rieck M, Arechiga A, Onengut-Gumuscu S et al. (2007). Genetic variation in PTPN22 
corresponds to altered function of T and B lymphocytes. Journal of Immunology, 179, 
4704-4710.  
Roitt I, Brostoff J, Male D (2002). Immunology (6th ed.). Mosby, an imprint of Elsevier Science 
Limited. 
Sanjeevi CB, Landin-Olsson M, Kockum I et al. (1995). Several residues in the DQA1 and 
DQB1 chain are either positively or negatively associated with insulin-dependent 
diabetes mellitus. Diabetes, 44, S1-S241. 
Sanjeevi CB, Falorni A, Kockum I et al. (1996). HLA and glutamic acid decarboxylase in 
human insulin-dependent diabetes mellitus. Diabetic Medicine, 13, 209-217. 
Seldin MF, Price AL (2008). Application of ancestry informative markers to association 
studies in European Americans. PLoS Genet, 4, e5. 
Senée V, Chelala C, Duchatelet S et al. (2006). Mutations in GLIS3 are responsible for a rare 
syndrome with neonatal diabetes mellitus and congenital hypothyroidism. Nature 
Genetics, 38, 682-687. 
Simoncic PD, Lee-Loy A, Barber DL et al. (2002). The T cell protein tyrosine phosphatase is a 
negative regulator of janus family kinases 1 and 3. Current biology, 12, 446-453.  
Skinningsrud B, Husebye ES, Gervin K et al. (2008). Mutation screening of PTPN22: 
association of the 1858T-allele with Addison’s disease. European Journal of Human 
Genetics, 16, 977-982. 
Skowera A, Ellis RJ, Varela-Calviňo R et al. (2008). CTLs are targeted to kill beta cells in 
patients with type 1 diabetes through recognition of a glucose-regulated 
preproinsulin epitope. Journal of Clinical Investigation, 118, 3390-3402.  
Smyth DJ, Plagnol V, Walker NM et al. (2008). Shared and distinct genetic variants in type 1 
diabetes and celiac disease. New England Journal of Medicine, 359, 2767-2777. 
Soranzo N, Spector TD, Mangino M et al. (2009). A genome-wide meta-analysis identifies 22 
loci associated with eight hematological parameters in the HaemGen consortium. 
Nature Genetics, 41, 1182-1190. 
www.intechopen.com
 
Genetics of Type 1 Diabetes 
 
629 
Suri A, Walters JJ, Gross ML et al. (2005). Natural peptides selected by diabetogenic DQ8 
and murine I-A(g7) molecules show common sequence specificity. Journal of Clinical 
Investigation, 115, 2268-2276. 
Svoren BM, Volkening LK, Wood JR et al. (2009). Significant vitamin D deficiency in youth 
with type 1 diabetes mellitus. Journal of Pediatrics, 154, 132-134. 
Swafford AD, Howson JM, Davison LJ et al. (2011). An allele of IKZF1 (Ikaros) conferring 
susceptibility to childhood acute lymphoblastic leukemia protects against type 1 
diabetes. Diabetes, 60, 1041-1044.   
Takaki S (2008). Sh2b3/Lnk family adaptor proteins in the regulation of 
lymphohematopoiesis. Japanese Journal of Clinical Immunology, 31, 440-447. 
Tobi EW, Lumey LH, Talens RP et al. (2009). DNA methylation differences after exposure to 
prenatal famine are common and timing- and sex-specific. Human Molecular 
Genetics, 18, 4046-4053.  
Todd JA, Walker NM, Cooper JD et al. (2007). Robust associations of four new chromosome 
regions from genome-wide analyses of type 1 diabetes. Nature Genetics, 39, 857-864.  
Todd JA (2010). Etiology of type 1 diabetes. Immunity, 32, 457-467. 
Turley SJ, Lee JW, Dutton-Swain N et al. (2005). Endocrine self and gut non-self intersect in 
the pancreatic lymph nodes. Proceedings of the National Academy of Sciences of the 
U.S.A., 102, 17729-17733. 
Ueda H, Howson JM, Esposito L et al. (2003). Association of the T-cell regulatory gene 
CTLA4 with susceptibility to autoimmune disease. Nature, 423, 506-511. 
Vaarala O, Atkinson MA, Neu J (2008). The “perfect storm” for type 1 diabetes: the complex 
interplay between intestinal microbiota, gut permeability and mucosal immunity. 
Diabetes, 57, 2555-2562. 
Vafiadis P, Bennett ST, Todd JA et al. (1997). Insulin expression in human thymus is 
modulated by INS VNTR alleles at the IDDM2 locus. Nature Genetics, 15, 289-292. 
Vandiedonck C, Capdevielle C, Giraud M et al. (2006). Association of the PTPN22*R620W 
polymorphism with autoimmune myasthenia gravis. Annals of Neurology, 59, 404-
407. 
Vang T, Congia M, Macis MD et al. (2005). Autoimmune-associated lymphoid tyrosine 
phosphatase is a gain-of-function variant. Nature Genetics, 37, 1317-1319.   
Vang T, Miletic AV, Arimura Y et al. (2008). Protein tyrosine phosphatases in autoimmunity. 
Annual Review of Immunology, 26, 29-55. 
van Ham M, van Lith M, Griekspoor A et al. (2000). What to do with HLA-DO? 
Immunogenetics, 51, 765-770. 
van der Auwera BJ, Vandewalle CL, Schuit FC et al. (1997). CTLA-4 gene polymorphism 
confers susceptibility to insulin-dependent diabetes mellitus (IDDM) 
independently from age and from other genetic or immune disease markers. The 
Belgian Diabetes Registry. Clinical and Experimental Immunology, 110, 98-103. 
Velaga MR, Wilson V, Jennings CE et al. (2004). The codon 620 tryptophan allele of the 
lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves’ 
disease. Journal of Clinical Endocrinology and Metabolism, 89, 5862-5865.  
Vijayakrishnan L, Slavik JM, Illes Z et al. (2004). An autoimmune disease-associated CTLA-4 
splice variant lacking the B7 binding domain signals negatively in T cells. Immunity, 
20, 563-575.  
von Herrath M (2009). Diabetes: A virus-gene collaboration. Nature, 459, 518-519. 
www.intechopen.com
 
Type 1 Diabetes – Pathogenesis, Genetics and Immunotherapy 
 
630 
Wallace C, Smyth DJ, Maisuria-Armer M et al. (2010). The imprinted DLK1-MEG3 gene 
region on chromosome 14q32.2 alters susceptibility to type 1 diabetes. Nature 
Genetics, 42, 68-71.  
Wang Z, Schones DE, Zhao K (2009). Characterization of human epigenomes. Current 
Opinion in Genetics & Development, 19, 127-134. 
Waterland RA, Lin JR, Smith CA et al. (2006). Post-weaning diet affects genomic imprinting 
at the insulin-like growth factor 2 (Igf2) locus. Human Molecular Genetics, 15, 705-
716. 
Wellcome Trust Case Control Consortium (2007). Genome-wide association study of 14,000 
cases of seven common diseases and 3,000 shared controls. Nature, 447, 661-678.   
Wen L, Ley RE, Volchkov PY et al. (2008). Innate immunity and intestinal microbiota in the 
development of type 1 diabetes. Nature, 455, 1109-1113. 
Wicker LS, Chamberlain G, Hunter K et al. (2004). Fine mapping, gene content, comparative 
sequencing, and expression analyses support Ctla4 and Nramp1 as candidates for 
Idd5.1 and Idd5.2 in the nonobese diabetic mouse. Journal of Immunology, 173, 164-
173. 
Wicker LS, Clark J, Fraser HI et al. (2005). Type 1 diabetes genes and pathways shared by 
humans and NOD mice. Journal of Autoimmunity, 25 (Suppl.), 29-33.  
Willcox A, Richardson SJ, Bone AJ et al. (2009). Analysis of islet inflammation in human type 
1 diabetes. Clinical and Experimental Immunology, 155, 173-181. 
Wing K, Onishi Y, Prieto-Martin P et al. (2008). CTLA-4 control over Foxp3+ regulatory T 
cell function. Science, 322, 271-275. 
Zhang L, Nakayama M, Eisenbarth GS (2008). Insulin as an autoantigen in NOD/human 
diabetes. Current Opinion in Immunology, 20, 111-118. 
www.intechopen.com
Type 1 Diabetes - Pathogenesis, Genetics and Immunotherapy
Edited by Prof. David Wagner
ISBN 978-953-307-362-0
Hard cover, 660 pages
Publisher InTech
Published online 25, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book is a compilation of reviews about the pathogenesis of Type 1 Diabetes. T1D is a classic autoimmune
disease. Genetic factors are clearly determinant but cannot explain the rapid, even overwhelming expanse of
this disease. Understanding etiology and pathogenesis of this disease is essential. A number of experts in the
field have covered a range of topics for consideration that are applicable to researcher and clinician alike. This
book provides apt descriptions of cutting edge technologies and applications in the ever going search for
treatments and cure for diabetes. Areas including T cell development, innate immune responses, imaging of
pancreata, potential viral initiators, etc. are considered.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Marie Cerna (2011). Genetics of Type 1 Diabetes, Type 1 Diabetes - Pathogenesis, Genetics and
Immunotherapy, Prof. David Wagner (Ed.), ISBN: 978-953-307-362-0, InTech, Available from:
http://www.intechopen.com/books/type-1-diabetes-pathogenesis-genetics-and-immunotherapy/genetics-of-
type-1-diabetes-2
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
